Skip to main content
GenSight Biologics S.A. logo

GenSight Biologics S.A. — Investor Relations & Filings

Ticker · SIGHT ISIN · FR0013183985 LEI · 549300NK4AB8OUEX1F54 PA Manufacturing
Open in API
Filings indexed 628 across all filing types
Latest filing 2024-09-23 Earnings Release
Country FR France
Listing PA SIGHT

About GenSight Biologics S.A.

https://www.gensight-biologics.com

GenSight Biologics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative gene therapies for patients with neurodegenerative retinal diseases and disorders of the central nervous system. The company's therapeutic approach is based on two core technology platforms: the Mitochondrial Targeting Sequence (MTS) and optogenetics. Its lead product candidate, LUMEVOQ (lenadogene nolparvovec), is a gene therapy in late-stage clinical development for treating vision loss from rare mitochondrial diseases. The company's pipeline also includes GS030, an optogenetic-based therapy in clinical trials for retinal degenerative diseases.

Recent filings

Filing Released Lang Actions
Inside Information / News release on accounts, results
Earnings Release Classification · 100% confidence The document explicitly states its purpose in the main heading: "GenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates". It contains detailed IFRS financial tables comparing H1 2023 and H1 2024 results (Revenues, Operating loss, Net income, Cash flows) and provides management commentary on these results. This structure and content are characteristic of a comprehensive financial report covering a period shorter than a full year. Therefore, it classifies as an Interim / Quarterly Report (IR). It is not just an Earnings Release (ER) because it includes detailed financial statements and extensive operational commentary, nor is it the Annual Report (10-K). H1 2024
2024-09-23 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 100% confidence The document is titled "GenSight Biologics publie ses résultats financiers du premier semestre 2024 et un point sur ses activités" (GenSight Biologics publishes its first half 2024 financial results and a business update). It contains detailed IFRS financial tables for the first half (S1) of 2024 compared to S1 2023, including revenue, operating expenses, net result, and cash flow statements. The text explicitly mentions that the financial statements have been reviewed and will be filed as the 'Rapport Financier Semestriel' (Half-Year Financial Report) before September 30, 2024. A comprehensive report covering a period shorter than a year (six months) is classified as an Interim / Quarterly Report (IR). Although it is presented as a press release, the core content is the detailed half-year financial results, making IR the most appropriate classification over ER (Earnings Release, which is usually just highlights) or RPA (Report Publication Announcement, as this document contains the results themselves, not just the announcement of the report). H1 2024
2024-09-23 French
Franchissement de seuils
Major Shareholding Notification Classification · 98% confidence The document is titled "Déclaration de franchissement de seuils (articles L. 233-7 du code de commerce)" which translates to 'Declaration of crossing thresholds (Articles L. 233-7 of the Commercial Code)'. This type of filing in France (indicated by the reference to the AMF and the Commercial Code) reports changes in significant share ownership, where an investor crosses a threshold (like 5%). This directly corresponds to the definition of Major Shareholding Notification (MRQ), which covers 'Notification of changes in significant share ownership levels (crossing thresholds)'. The document details that Armistice Capital, LLC crossed below the 5% threshold on August 26, 2024, and reports their current holding.
2024-09-20 French
Franchissement de seuils
Major Shareholding Notification Classification · 98% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" which translates to a declaration of crossing shareholding thresholds, referencing French commercial code. It explicitly states that The Goldman Sachs Group, Inc. crossed below the 5% threshold of capital and voting rights of GENSIGHT BIOLOGICS S.A. This type of filing, reporting changes in significant share ownership that cross regulatory thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document length is short (1219 chars), but the content is the declaration itself, not an announcement of a separate report, so RPA/RNS is less appropriate than the specific filing type.
2024-09-17 French
Inside Information / News release on accounts, results
Capital/Financing Update Classification · 99% confidence The document is explicitly titled as a "Press Release" and its content focuses on reporting the company's cash position as of a specific date (June 30, 2024) and providing a business update, including manufacturing progress and working capital outlook. This structure—announcing key financial metrics (cash position) and operational milestones outside of a formal quarterly/annual report filing—is characteristic of an Earnings Release (ER). It is not a full comprehensive report (like 10-K or IR), nor is it a transcript (CT) or a general regulatory announcement (RNS). It is the initial announcement of period-end financial highlights.
2024-07-23 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 95% confidence The document is titled "GenSight Biologics publie sa position de trésorerie au 30 juin 2024, et fait le point sur ses activités" (GenSight Biologics publishes its cash position as of June 30, 2024, and provides an update on its activities). It details the cash position (€6.9 million as of June 30, 2024), recent financing activities (capital increase in May 2024), working capital status, and operational updates regarding the LUMEVOQ® drug manufacturing and compassionate access program restart. This content structure—a periodic update on financial health (cash position, working capital) combined with key operational milestones—is characteristic of an Earnings Release (ER) or potentially an Interim Report (IR) if it were a comprehensive quarterly filing. However, since it focuses specifically on the cash position and operational highlights rather than a full set of financial statements for a period, it aligns best with an initial announcement of period-end results, which is the definition of an Earnings Release (ER). It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR), nor is it merely an announcement of a report (RPA). H1 2024
2024-07-23 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.